MED1

Across TCGA pan-cancer cohorts, MED1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MED1 data layer compared with 28 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MED1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MED1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and COAD show a favorable association.

LUAD, COAD, and LSCC are the cancer types where MED1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.859	0.373	.007	35	view →
COAD	DFS	Median	All	1.000	0.918	.016	24	view →
LSCC	OS	Tertile	II,III,IV	0.945	0.571	.009	14	view →
HNSC	OS	Median	All	0.630	0.811	.020	5	view →
PDAC	DFS	Tertile	III,IV	0.384	0.757	.048	3	view →
CCRCC	DFS	Tertile	All	0.867	0.979	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MED1–LUAD (DFS)

Open the LUAD breakdown →